Open Access

Xenografts derived from patients with head and neck cancer recapitulate patient tumour properties

  • Authors:
    • Haruna Makita
    • Kazuhira Endo
    • Yoshiya Kasahara
    • Asuka Nakata
    • Makiko  Moriyama‑Kita
    • Kazuya Ishikawa
    • Takayoshi Ueno
    • Yosuke Nakanishi
    • Satoru Kondo
    • Naohiro Wakisaka
    • Noriko Gotoh
    • Tomokazu Yoshizaki
  • View Affiliations

  • Published online on: March 16, 2021     https://doi.org/10.3892/ol.2021.12646
  • Article Number: 385
  • Copyright: © Makita et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Rodent models mimic the heterogeneity of head and neck cancer (HNC) malignancies and are used to investigate HNC‑associated biomarkers and evaluate drug responses. To assess the utility of patient‑derived xenografts (PDXs) as an HNC model, 18 tumour samples were obtained from surgical specimens of patients with HNC and implanted into non‑obese diabetic severe combined immunodeficient mice. The histological features of PDXs and corresponding patient samples were compared. Furthermore, the present study investigated how PDX responses to anticancer drugs mimic patient clinical responses, as well as the expression of adenosine triphosphate‑binding cassette transporters through chemotherapy in an HNC‑PDX model. A total of five PDXs from patients with HNC exhibiting high correspondence with histopathological features of the original patient samples were established (establishment rate, 28%). The responses of three PDXs to cisplatin were associated with clinical responses of the patients. ABC transporter expression was augmented in one PDX model after anticancer drug treatment, but not in PBS‑treated passaged PDXs. PDX models exhibited similar biological and chemosensitive characteristics to those of the primary tumours. PDXs could be a useful preclinical tool to test novel therapeutic agents and identify novel targets and biomarkers in HNC.
View Figures
View References

Related Articles

Journal Cover

May-2021
Volume 21 Issue 5

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Makita H, Endo K, Kasahara Y, Nakata A, Moriyama‑Kita M, Ishikawa K, Ueno T, Nakanishi Y, Kondo S, Wakisaka N, Wakisaka N, et al: Xenografts derived from patients with head and neck cancer recapitulate patient tumour properties. Oncol Lett 21: 385, 2021
APA
Makita, H., Endo, K., Kasahara, Y., Nakata, A., Moriyama‑Kita, M., Ishikawa, K. ... Yoshizaki, T. (2021). Xenografts derived from patients with head and neck cancer recapitulate patient tumour properties. Oncology Letters, 21, 385. https://doi.org/10.3892/ol.2021.12646
MLA
Makita, H., Endo, K., Kasahara, Y., Nakata, A., Moriyama‑Kita, M., Ishikawa, K., Ueno, T., Nakanishi, Y., Kondo, S., Wakisaka, N., Gotoh, N., Yoshizaki, T."Xenografts derived from patients with head and neck cancer recapitulate patient tumour properties". Oncology Letters 21.5 (2021): 385.
Chicago
Makita, H., Endo, K., Kasahara, Y., Nakata, A., Moriyama‑Kita, M., Ishikawa, K., Ueno, T., Nakanishi, Y., Kondo, S., Wakisaka, N., Gotoh, N., Yoshizaki, T."Xenografts derived from patients with head and neck cancer recapitulate patient tumour properties". Oncology Letters 21, no. 5 (2021): 385. https://doi.org/10.3892/ol.2021.12646